

EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors

NCT06541639

Status	RECRUITING
Phase	Phase 1
Sponsor	Peking University
Enrollment	78 participants

Key Eligibility Criteria

Inclusion (8)

- Recurrent or metastatic solid tumors that have been histologically or cytologically pathologically confirmed and are not amenable to radical treatment with surgery or local therapy.
 - Patients with advanced or recurrent solid tumors who have failed prior standard therapy.
 - Expected survival period ≥ 6 weeks at the time of informed consent.
 - Adequate organ function
 - Eastern Cooperative Oncology Group (ECOG) Physical Status Score 0 to 1.
- ... and 3 more (see full listing online)

Exclusion (13)

- Primary central nervous system (CNS) malignancies that are symptomatic, untreated, or in need of curative treatment, or subjects with CNS metastases.
 - Uncontrolled co-morbidities.
 - Cerebrovascular event (stroke, transient ischemic attack, etc.) within 4 months prior to the signing of informed consent form.
 - In screening period male QTcF interval ≥ 450 ms; Female QTcF interval ≥ 470 ms (calculated by the Fridericia formula).
 - Left ventricular ejection fraction (LVEF) $< 50\%$ during the screening period.
- ... and 8 more (see full listing online)

Locations (2 total)

Beijing Cancer Hospital, Beijing, Beijing Municipality, China
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China